Xenon Advances Epilepsy Drug as Quarterly Loss Widens
The company ended June with about $1.2 billion in cash and securities, funding operations into 2029.
Xenon Pharmaceuticals (XENE), a clinical-stage neuroscience company, advanced its lead epilepsy treatment toward a regulatory filing as higher development spending widened its second-quarter loss.
The quarter marked a shift from late-stage clinical validation to preparations for potential approval. Xenon completed a pre-NDA meeting with the Food and Drug Administration for azetukalner after reporting positive Phase 3 results in March, and its application remains on track for submission in the third quarter of 2026.
Revenue remained at zero, unchanged from a year earlier, while the net loss widened 31% to $110.7 million from $84.7 million. For the first six months of 2026, revenue fell to zero from $7.5 million as collaboration revenue from Neurocrine Biosciences declined.
Research-and-development expense rose 32% to $99.2 million, driven by azetukalner Phase 3 studies, manufacturing tied to the planned application, early-stage pain programs and personnel costs. General-and-administrative expense increased 24% to $23.9 million, and the operating loss widened 31% to $123.2 million. Higher interest income lifted other income 33% to $11.8 million, partly offsetting the increased spending.
Azetukalner reduced monthly focal-onset-seizure frequency 53.2% at the 25-milligram dose and 34.5% at 15 milligrams in the X-TOLE2 study, compared with 10.4% for placebo. The higher dose produced a 42.7% placebo-adjusted reduction, an 8.1-percentage-point improvement from the earlier Phase 2b study.
Xenon also began a Phase 1 study of XEN1720, making it the company’s second clinical-stage NaV1.7 pain candidate. Neurocrine’s partnered NBI-921355 program advanced to an ongoing Phase 1b study, with data expected in 2027.
The company’s cash-runway outlook remains into 2029, sustaining the extension announced in the first quarter. Xenon expects to complete enrollment outside Japan in the X-TOLE3 study during 2026, while several other azetukalner trials continue enrolling; topline results from the X-NOVA2 depression study remain expected in the first half of 2027.